Poster Presenter: Jose A. Gómez-Puerta, MD, PhD, MPH, Rheumatology Department, Hospital Clinic Barcelona, Spain
Poster Title: Vaccination Against SARS-CoV-2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry
Ignite Session 6C
Sunday, November 13 | 2:35–2:40 p.m. ET | South Philly Stage
All ACR Convergence 2022 poster presentations are available on demand to registered meeting participants through October 31, 2023.
What is your poster about?
We evaluated the safety of vaccines against SARS-CoV-2 in people with systemic autoimmune diseases (SAD) such as systemic lupus erythematosus, Sjögren’s syndrome, and systemic vasculitis, among others, analyzing data from the European Alliance of Associations for Rheumatology (EULAR) Coronavirus Vaccine (COVAX) physician-reported registry.
Why did you decide to investigate this topic?
Because there are some concerns about the use of vaccines against SARS-CoV-2 in patients with SAD, including the risk of serious adverse events in a particular group of patients who are more prone to the development of immunomediated events such as thrombosis, arthritis, or skin rashes, among others.
What are you working on next related to this research?
We are comparing the safety of vaccines against SARS-CoV-2 among patients with inflammatory joint diseases (i.e., rheumatoid arthritis), non-inflammatory rheumatic diseases, and SAD.
What excites you most about your work?
After evaluating hundreds of patients included in our registry, we are transmitting a message of safety and tranquility for patients with SAD, reinforcing the idea of the importance of vaccination in this population group susceptible to severe infection by COVID-19.
CONTINUE YOUR ACR EXPERIENCE ON DEMAND
Watch sessions you may have missed during ACR Convergence 2022 or rewatch sessions on topics you want to revisit on the virtual meeting website. All in-person and virtual participants have access to on-demand recordings of scientific sessions, virtual posters, and more through October 31, 2023.